Why the study?
Primary hepatic angiosarcoma is a rare and aggressive tumor with no established treatment guidelines and poor prognosis.
Does pazopanib plus PD-1 inhibitor and RAK cells improve tumor response in a patient with advanced primary hepatic angiosarcoma?
Case Report (n=1)
No
Does pazopanib plus PD-1 inhibitor and RAK cells improve tumor response in a patient with advanced primary hepatic angiosarcoma?
Pazopanib combined with a PD-1 inhibitor and RAK cells may be a viable treatment option for advanced primary hepatic angiosarcoma.
May support this regimen in advanced hepatic angiosarcoma; leaves open efficacy confirmation in prospective trials.
BACKGROUND: Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA. CASE PRESENTATION: A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15 months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor. CONCLUSION: Pazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA.
No takes yet. Share an insight, caveat, or question.
Qiao et al. (2018) conducted a case report in Primary hepatic angiosarcoma (n=1). Pazopanib, pembrolizumab, and RAK cells was evaluated on Tumor response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: